Retatrutide cost predictions — anyone have experience?

newstart_MO said:

The glucagon component looks paradoxical and is not.

Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.

From the other side of the consultation, briefly. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

VendorMark said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

I read this differently from VendorMark, on substance rather than tone. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

One concrete data point for the thread. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.